Related Experiment Video
Updated: Oct 26, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Evidence based review of management of cardiorenal syndrome type 1
1Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Wilayah Persekutuan Kuala Lumpur, Malaysia. leotungong@gmail.com.
Insights
Cardiorenal syndrome (CRS) type 1, a complication of acute decompensated heart failure, requires better management strategies. Early recognition and treatment of CRS type 1 can significantly improve patient outcomes.
Area of Science:
- Nephrology
- Cardiology
- Critical Care Medicine
Background:
- Cardiorenal syndrome (CRS) type 1 involves acute kidney injury in acute decompensated heart failure.
- It leads to increased hospitalization, morbidity, and mortality.
- Pathophysiology is complex, involving hemodynamic, neurohormonal, inflammatory, and infectious factors.
Purpose of the Study:
- To review current management strategies for CRS type 1.
- To highlight the limited evidence and guidelines available.
- To discuss various therapeutic options based on existing literature.
Main Methods:
- Review of six clinical studies on CRS type 1 treatments.
- Analysis of strategies including nesiritide, dopamine, levosimendan, tolvaptan, dobutamine, and ultrafiltration.
Main Results:
- Established treatments primarily focus on symptomatic relief of heart failure.
- Evidence for specific CRS type 1 management is limited.
- Therapeutic strategies are derived from current literature.
Conclusions:
- Early recognition and treatment of CRS type 1 are crucial.
- Improved management can significantly enhance patient outcomes.
- Further research and guidelines are needed for optimal care.
Abstract:
Cardiorenal syndrome (CRS) type 1 is the development of acute kidney injury in patients with acute decompensated heart failure. CRS often results in prolonged hospitalization, a higher rate of rehospitalization, high morbidity, and high mortality. The pathophysiology of CRS is complex and involves hemodynamic changes, neurohormonal activation, hypothalamic-pituitary stress reaction, inflammation, and infection. However, there is limited evidence or guideline in managing CRS type 1, and the established therapeutic strategies mainly target the symptomatic relief of heart failure. This review will discuss the strategies in the management of CRS type 1. Six clinical studies have been included in this review that include different treatment strategies such as nesiritide, dopamine, levosimendan, tolvaptan, dobutamine, and ultrafiltration. Treatment strategies for CRS type 1 are derived based on the current literature. Early recognition and treatment of CRS can improve the outcomes of the patients significantly.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Chronic Kidney Disease IV: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management

